- Home
- AUTL vs TRVI Comparison
AUTL vs TRVI Comparison
Compare AUTL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- TRVI
- Stock Information
- Founded
- AUTL 2014
- TRVI 2011
- Country
- AUTL United Kingdom
- TRVI United States
- Employees
- AUTL N/A
- TRVI N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- TRVI Health Care
- Exchange
- AUTL Nasdaq
- TRVI Nasdaq
- Market Cap
- AUTL 625.4M
- TRVI 725.7M
- IPO Year
- AUTL 2018
- TRVI 2019
- Fundamental
- Price
- AUTL $1.38
- TRVI $8.21
- Analyst Decision
- AUTL Strong Buy
- TRVI Strong Buy
- Analyst Count
- AUTL 5
- TRVI 9
- Target Price
- AUTL $9.12
- TRVI $20.72
- AVG Volume (30 Days)
- AUTL 4.4M
- TRVI 2.8M
- Earning Date
- AUTL 11-11-2025
- TRVI 11-05-2025
- Dividend Yield
- AUTL N/A
- TRVI N/A
- EPS Growth
- AUTL N/A
- TRVI N/A
- EPS
- AUTL N/A
- TRVI N/A
- Revenue
- AUTL $29,934,000.00
- TRVI N/A
- Revenue This Year
- AUTL $634.25
- TRVI N/A
- Revenue Next Year
- AUTL $93.16
- TRVI N/A
- P/E Ratio
- AUTL N/A
- TRVI N/A
- Revenue Growth
- AUTL 185.17
- TRVI N/A
- 52 Week Low
- AUTL $1.11
- TRVI $2.36
- 52 Week High
- AUTL $5.00
- TRVI $9.83
- Technical
- Relative Strength Index (RSI)
- AUTL 28.28
- TRVI 59.58
- Support Level
- AUTL $1.34
- TRVI $6.93
- Resistance Level
- AUTL $1.46
- TRVI $9.92
- Average True Range (ATR)
- AUTL 0.09
- TRVI 0.71
- MACD
- AUTL 0.01
- TRVI 0.19
- Stochastic Oscillator
- AUTL 9.09
- TRVI 57.86
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.